Description

Product Description

Background

Pirnabine is a synthetic cannabinoid receptor ligand developed for experimental studies of the endocannabinoid system. It exhibits selective binding affinity to CB1 and CB2 receptors, modulating ocular pressure and potentially providing neuroprotective effects in retinal tissue.

Cannabinoid receptor ligands have emerged as critical tools in ophthalmology research, particularly for diseases like glaucoma, where intraocular pressure (IOP) regulation is essential. Pirnabine’s chemical structure allows precise receptor interaction, making it a preferred molecule in preclinical studies for ocular pharmacology.

Chemical Nature and Structure

• Type: Synthetic cannabinoid ligand

• Target Receptors: CB1 and CB2

• Form: Free acid or acetate depending on synthesis

• Mechanism: Modulates endocannabinoid receptor pathways to influence ocular pressure and neuroinflammation

The compound is designed for high water solubility and laboratory stability, ensuring reproducibility in in vitro and in vivo studies.

Research Significance

Pirnabine is valuable for:

• Glaucoma Research: Helps investigate cannabinoid-mediated intraocular pressure reduction.

• Neuroprotection Studies: Evaluates retinal ganglion cell survival under stress conditions.

• Ocular Pharmacology: Explores CB1/CB2 signaling pathways in ocular tissues.

• Endocannabinoid System Studies: Provides mechanistic insights into receptor-ligand interactions.

Compared to other cannabinoid ligands, Pirnabine shows enhanced receptor specificity, reducing off-target effects and providing more reliable preclinical data.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Pirnabine selectively binds to CB1 and CB2 cannabinoid receptors, initiating intracellular signaling cascades. Through CB1 receptor activation, Pirnabine can modulate neuronal calcium channels, affecting neurotransmitter release and providing potential neuroprotective effects. CB2 receptor interaction is associated with anti-inflammatory effects, particularly relevant in retinal microglia modulation.

Research Applications

1. Glaucoma Studies:

   • Reduces intraocular pressure by modulating aqueous humor outflow.

   • Evaluates neuroprotective mechanisms on retinal ganglion cells.

2. Endocannabinoid Signaling:

   • Investigates receptor-ligand binding specificity.

   • Helps map CB1/CB2 pathways in ocular and neuronal tissues.

3. Neuroprotection and Inflammation:

   • Reduces oxidative stress-induced retinal injury.

   • Modulates microglial activity in preclinical retinal models.

4. Drug Combination Models:

   • Used alongside other ocular therapeutics to evaluate synergistic effects.

   • Compatible with both in vitro cell culture and in vivo rodent models.

Pirnabine offers translational potential for glaucoma therapy research, enabling studies on disease mechanism, receptor pharmacology, and neuroprotective strategies.

Side Effects (For Reference in Research Models)

In laboratory and preclinical studies, Pirnabine demonstrates:

• Mild CNS-related effects: dose-dependent changes in locomotion in animal models.

• Transient changes in ocular physiology: minor irritation or temporary IOP fluctuations.

• Solvent-related variability: DMSO or buffer concentrations may affect efficacy.

• Receptor desensitization: prolonged high doses may lead to CB1/CB2 receptor tolerance.

These side effects are model-specific and do not represent clinical safety data. Proper experimental controls are recommended.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Pirnabine CAS 19825-63-9

• CB receptor ligand research

• Synthetic cannabinoid ligand GMP supplier

• Glaucoma research peptide

• Retinal neuroprotection peptide

• CB1/CB2 receptor modulator

• Preclinical ocular pharmacology research

• Laboratory cannabinoid ligand peptide

• Pirnabine GMP peptide supplier

• Endocannabinoid signaling research